The Pharmaceutical Year, and What the Corpus Cannot See in It

This file collects what the corpus recorded about pharmaceuticals in 2025 and what it could not.

Inotiv at 25-0819b, with employee and partner data. Novo Nordisk at 25-0912b, with trial participant records including biomarkers and immunogenicity data. BioPharma Services at 25-1127c, discovered in November and claimed by Qilin.

Three incidents, all confidentiality, all surfaced because personal data was involved.

Whether drug formulations or unpublished results were taken anywhere, at 25-0915b — no register would record it.

Whether any manufacturing record was altered, at 25-0921b — an integrity failure produces no notification, no outage and no listing.

Whether any research programme was delayed, at 25-0923c — the harm is deferred by years and distributed across people who will never know.

Whether the sector is affected disproportionately at all, at 25-0922b — three incidents among thousands of organisations establishes nothing.

This database sees what notification law surfaces. In pharmaceuticals that is trial participants and employees, and it is not obviously the most consequential material the sector holds.

The corpus reached the same conclusion for manufacturing at 25-1204, law firms at 25-0916, and corporate records at 25-1124b. Pharmaceuticals is where the gap between what is recorded and what matters is widest, because the unrecorded categories include a medicine arriving later than it would have.

Graded medium: a synthesis across a thin sector sample, and the corpus is explicit that it cannot size what it is missing.